Research Articles | Page 35 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes Jun 2024 Journal of Clinical Oncology Myelodysplastic Syndromes (MDS)
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 Apr 2020 Leukemia Research Reports Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study Jul 2020 Leukemia Research Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) Jan 2021 Cancer Causes & Control : CCC Myelodysplastic Syndromes (MDS)
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Mar 2021 Cancers Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS)
RNA splicing as a therapeutic target in myelodysplastic syndromes Dec 2024 Seminars in Hematology Myelodysplastic Syndromes (MDS)
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review Jul 2023 Experimental Hematology & Oncology Myelodysplastic Syndromes (MDS)
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome May 2024 Journal of Pediatric Hematology/Oncology Aplastic Anemia
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)